Literature DB >> 21160042

Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types.

Eugene Y Chiang1, Xin Yu, Jane L Grogan.   

Abstract

IL-1R-associated kinases (IRAKs) are important mediators of MyD88-dependent signaling by the TLR/IL-1R superfamily and facilitate inflammatory responses. IRAK4 and IRAK1 function as active kinases and as scaffolds for protein-protein interactions. We report that although IRAK1/4 kinase activity is essential for human plasmacytoid dendritic cell (pDC) activation, it is dispensable in B, T, dendritic, and monocytic cells, which is in contrast with an essential active kinase role in comparable mouse cell types. An IRAK1/4 kinase inhibitor abrogated TLR7/9-induced IFN-α responses in both mouse and human pDCs, but other human immune cell populations activated via TLR7/9 or IL-1R were refractory to IRAK4 kinase inhibition. Gene ablation experiments using small interfering RNA demonstrated an essential scaffolding role for IRAK1 and IRAK4 in MyD88-dependent signaling. Finally, we demonstrate that autoimmune patient (systemic lupus erythematosus and rheumatoid arthritis) serum activates both pDC and B cells, but IRAK1/4 kinase inhibition affects only the pDC response, underscoring the differential IRAK1/4 functional requirements in human immune cells. These data reveal important species differences and elaborate cell type requirements for IRAK1/4 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21160042     DOI: 10.4049/jimmunol.1002821

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Identification of a New Susceptibility Locus for Systemic Lupus Erythematosus on Chromosome 12 in Individuals of European Ancestry.

Authors:  F Yesim Demirci; Xingbin Wang; Jennifer A Kelly; David L Morris; M Michael Barmada; Eleanor Feingold; Amy H Kao; Kathy L Sivils; Sasha Bernatsky; Christian Pineau; Ann E Clarke; Rosalind Ramsey-Goldman; Timothy J Vyse; Patrick M Gaffney; Susan Manzi; M Ilyas Kamboh
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

2.  Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.

Authors:  Leah Cushing; Wayne Stochaj; Marshall Siegel; Robert Czerwinski; Ken Dower; Quentin Wright; Margaret Hirschfield; Jean-Laurent Casanova; Capucine Picard; Anne Puel; Lih-Ling Lin; Vikram R Rao
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

3.  IRAK1, a potential therapeutic target for rheumatoid arthritis?

Authors:  Qiang Xie; Shi-Cun Wang; Jun Li
Journal:  Rheumatol Int       Date:  2012-11-05       Impact factor: 2.631

4.  Dual Inhibition of Rip2 and IRAK1/4 Regulates IL-1β and IL-6 in Sarcoidosis Alveolar Macrophages and Peripheral Blood Mononuclear Cells.

Authors:  Jaya Talreja; Harvinder Talwar; Nisar Ahmad; Ruchi Rastogi; Lobelia Samavati
Journal:  J Immunol       Date:  2016-07-11       Impact factor: 5.422

5.  Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes.

Authors:  Ryan D Molony; Jenny T Nguyen; Yong Kong; Ruth R Montgomery; Albert C Shaw; Akiko Iwasaki
Journal:  Sci Signal       Date:  2017-12-12       Impact factor: 8.192

6.  A novel synthetic derivative of squamosamide FLZ inhibits the high mobility group box 1 protein-mediated neuroinflammatory responses in murine BV2 microglial cells.

Authors:  De-Chuan Li; Xiu-Qi Bao; Xiao-Liang Wang; Hua Sun; Dan Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-03-09       Impact factor: 3.000

7.  Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.

Authors:  Michael Murphy; Goutham Pattabiraman; Tissa T Manavalan; Andrei E Medvedev
Journal:  Eur J Immunol       Date:  2017-03-31       Impact factor: 5.532

8.  Targeting IRAK4 for Degradation with PROTACs.

Authors:  Joao Nunes; Grant A McGonagle; Jessica Eden; Girieshanie Kiritharan; Megane Touzet; Xiao Lewell; John Emery; Hilary Eidam; John D Harling; Niall A Anderson
Journal:  ACS Med Chem Lett       Date:  2019-06-14       Impact factor: 4.345

9.  Association between interleukin-1 receptor associated kinase 1 rs3027898 A/C gene polymorphism and rheumatoid arthritis.

Authors:  Mahdi Atabaki; Mohammad Hashemi; Hamid Daneshvar; Ebrahim Alijani
Journal:  Biomed Rep       Date:  2017-02-09

Review 10.  Toll-like receptors: potential targets for lupus treatment.

Authors:  Yan-wei Wu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.